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Background: To analyze patterns of local-regional failure after primary intensity modulated radiotherapy (IMRT) for
nasopharyngeal carcinoma (NPC).
Methods: A total of 370 non-metastatic NPC patients consecutively treated with IMRT (with or without chemotherapy)
were analyzed. Radiotherapy was administered using a simultaneous integrated boost (SIB) technique at the total
prescribed dose of 66-70.4Gy (2.0-2.2Gy per fraction). The location and extent of local-regional failures were transferred
to the pretreatment planning computed tomography (CT) for dosimetric analysis. The dose of radiation received by
Vrecur (volume of recurrence) was calculated and analyzed with dose-volume histogram (DVH). Failures were classified
as: “in field” if 95% of Vrecur was within the 95% isodose, “marginal” if 20% to 95% of Vrecur was within the 95% isodose,
or “outside” if less than 20% of Vrecur was inside the 95% isodose.
Results: With a median follow up of 26 months, 25 local-regional failures were found in 18 patients. The 1- and 2-year
actuarial local-regional control rates for all patients were 99.7% and 95.5% respectively. Among the 22 local–regional
failures with available diagnostic images, 16 (64%) occurred within the 95% isodose lines and were considered in-field
failures; 3 (12%) were marginal and 3 (12%) were outside-field failures.
Conclusions: Intensity-modulated radiotherapy provides excellent local-regional control for NPC. In-field failures are the
main patterns for local-regional recurrence. Reducing the coverage of critical adjacent tissues in CTV purposefully for
potential subclinical diseases was worth of study. Great attention in all IMRT steps is necessary to reduce potential
causes of marginal failures. More studies about radioresistance are needed to reduce in-field failures.
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Intensity-modulated radiotherapy (IMRT) is a major
breakthrough in the treatment of NPC [1]. It is capable
of improving dose conformity for complex tumor targets
and better protection for the adjacent organs. Encour-
aging results with IMRT have been consistently reported
[1-15]. Kwong [16] and Su [4] reported a 3- and 5- year
local control rate of 100% and 97.7% for early-stage NPC
treated with IMRT alone. For locally advanced NPC, 2-
and 5-year local control rate of 95.7% [12] and 94.9% [7]
can be achieved after effective chemoradiotherapy.* Correspondence: yinghongmei2013@163.com
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reproduction in any medium, provided the orHowever, distant metastasis and post-treatment re-
lapse remain as the main causes for NPC deaths. In
2000, Dawson et al. [17] firstly demonstrated that the
majority (75%) of local-regional relapses after IMRT as
the primary treatment for head and neck cancer were
in-field, in areas of previous disease which was judged to
be at high risk at the time of RT planning. Their findings
then motivate studies of dose escalation to the highest
risk regions. Eleven years later, Ng et al. [1] reported
similar failure patterns in NPC patients. Furthermore,
they found that the locoregional failure rate was signifi-
cantly related to the minimum target dose, and it was
recommended to deliver at least 66.5Gy to the target
volumes. A recent study by Orlandi et al. [18] showed
that apart from the above factors, overall treatment timetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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changes during RT could also affect treatment results.
It is worthy of discussion because IMRT planning is
usually associated with sharp dose gradients outside the
target volumes; therefore, an inadequate definition of tar-
get volumes could increase the risk of geographic misses,
which eventually lead to local-regional recurrence [18]. In
addition, a case series reported by Cannon and Lee [19]
showed that the risk of marginal miss may be increased
when excessive parotid gland sparing was pursued.
The aim of this study is to analyze the local-regional
failure patterns following IMRT for NPC in our institu-
tion. This analysis allows us to assess the adequacy and
the overall quality of the treatment technique.
Methods
Patients and pretreatment evaluations
From December 2007 to April 2012, 370 newly diag-
nosed non-metastatic NPC patients treated by definitive
IMRT in Shanghai Cancer Center of Fudan University
were enrolled in this study. All patients underwent dis-
ease restaging using the AJCC 2010 staging system. This
study was approved by the Institutional Review Boards
of Fudan University Shanghai Cancer Center. Written
informed consent was obtained from the patient for the
publication of this report and any accompanying images.
Intensity-modulate radiotherapy
Immobilization and simulation
Patients were immobilized in the supine position with a
thermoplastic head and shoulder mask. Intravenous
contrast-enhanced CT using slice thickness of 5 mm
was performed for planning. Image fusion of the T1 se-
quences with gadolinium enhanced MRI was performed
with the CT simulation images for target delineation.
The CT data were imported to treatment planning sys-
tem for treatment design.
Target delineation
The target volumes were defined in accordance with the
International Commission on Radiation Units and Mea-
surements Reports 50 and 62 [20,21]. The primary gross
tumor volume (GTV_P) and involved lymph nodes
(GTV_N) included all gross tumors was determined by
imaging, clinical, and endoscopic findings. The enlarged
retropharyngeal nodes were outlined together with pri-
mary GTV, as the GTV_P on the IMRT plans. For pa-
tients who received neoadjuvant chemotherapy, the pre-
chemotherapy volume of the primary lesion was used for
GTV-P delineation,and the post-chemotherapy volume of
the lymph nodes was used for GTV-N delineation.
The clinical target volume (CTV) was defined as the
GTV plus 5- to 10-mm margin to encompass any micro-
scopic extension, together with the regional lymphatics.Two clinical target volumes (CTVs) were defined in our
radiotherapy: CTV1 and CTV2. The CTV1 was defined
as the high-risk region that included GTV_P plus 5- to
10-mm margin; CTV1 should also encompass the entire
nasopharynx, skull base, parapharyngeal space, retro-
pharyngeal lymph nodal regions, the anterior second of
the clivus, inferior sphenoid sinus, pterygoid fossae, the
posterior third of the nasal cavity and maxillary sinuses,
and any high risk nodal regions, including the bilateral
upper deep jugular nodes, and the near station of the
positive lymph nodes. Neck levels IB (submandibular
nodes) were selectively irradiated only if there was ex-
tensive nodal disease on the ipsilateral IIA/IIB region,
extracapsular extension of the IIA lymph nodes, or ton-
silla and lingual root involved by the primary tumor.
The levels IA (submental nodes) were delineated only if
the submandibular nodes or oral cavity were grossly in-
volved by disease. The low-risk CTV (CTV2) referred to
levels IV and Vb without metastatic cervical lymph
nodes. There were two corresponding PTV_Cs in our
radiotherapy: PTV_C1 (CTV1 +3 mm) and PTV_C2
(CTV2 +3 mm). The PTV_Cs would encompass the cor-
responding CTV with a 3-mm margin in all directions.
However, when the CTV was near critical organs, such
as the brainstem, spinal cord, PTV_C was generated as
small as 1 mm.
The organs at risk (OAR) include the spinal cord,
brain stem, optic chiasm, optic nerves, eyeballs, lens,
temporal lobes, parotid glands, oral mucosa, larynx and
temporomandibular joints. A 5-mm margin was added
to the spinal cord and brainstem during optimization to
form the planning organ-at-risk volume (PRV).
Treatment planning and delivery
All patients were treated with external-beam radiation
therapy using 6-MV photons, 7-9 radiation fields. The
treatment technique was simultaneous integrated boost
(SIB) technique. The dose prescribed to PTV-G (GTV
+5 mm) was 66Gy in 30 fractions for T1–T2 disease,
70.4Gy in 32 fractions for T3–T4 disease, and 66Gy in
30 or 32 fractions for lymph nodes involved by disease.
The dose delivered to PTV-C1and PTV-C2 was 60Gy
and 54Gy, respectively. All patients were treated one
fraction per day, 5 days per week.
Chemotherapy
About 92.2% patients received cisplatin based chemo-
therapy including neoadjuvant chemotherapy, concur-
rent chemotherapy and adjuvant chemotherapy. The
most common regimen of neoadjuvant and adjuvant
chemotherapy included two to three cycles of TP (doce-
taxel 60 mg/m2/day, day 1, cisplatin 25 mg/m2/day, days
1–3), TPF (docetaxel 60 mg/m2/day, day 1, cisplatin
25 mg/m2/day, days 1–3, and 5-fluorouracil 0.5 g/m2
























IMRT treatment duration (days)
Median (range) 45 (40–58)
RT alone 29 (7.8)
Chemotherapy 341 (92.2)
WHO World Health Organization, RT radiotherapy.
aOther WHO histologic type including nasopharyngeal adenoid cystic
carcinoma, poorly differentiated adenocarcinoma, small cell carcinoma and
carcinomatous change.
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day 8, cisplatin 25 mg/m2/day, days 1–3) regimen. In-
duction chemotherapy was given every 3 weeks. Four
weeks after the completion of RT, the adjuvant chemo-
therapy was administered every 3 weeks. Concurrent
chemotherapy consisting of 80 mg/m2, days 1–3 of cis-
platin, every 3 weeks for 2 to 3 cycles.
Patient evaluation
All patients were evaluated weekly for treatment re-
sponse and toxicity during radiation therapy. After
IMRT, patients were clinically evaluated at predefined
intervals, typically every 3 months in the first 2 years,
every 6 months from the third year to the fifth year, and
annually thereafter. Each follow-up included indirect
mirror examination for the nasopharynx and palpation
of neck nodes. MRI of the nasopharynx, chest CT scan,
and ultrasound of abdomen were performed 3 months
after the completion of IMRT and every 6–12 months
thereafter. Additional tests were ordered when indicated
to evaluate local or distant relapse.
Definition of failure site
For patients with local-regional failure, the recurrent
tumor volume (Vrecur) was identified on MRI scans or
CT scans obtained at the time when recurrence was di-
agnosed and transferred to the pretreatment planning
CT. The exact site and extent of each tumor were then
compared with the pretreatment planning CT data sets,
focusing on the 95% isodose lines. The dose of radiation
received by Vrecur was calculated and analyzed with
dose-volume histogram (DVH). The failures were cate-
gorized as occurring inside or outside the high dose tar-
get volume, depending on the location of Vrecur: “in
field” if 95% of Vrecur was within the 95% isodose, “mar-
ginal” if 20% to 95% of Vrecur was within the 95% iso-
dose, or “outside” if less than 20% of Vrecur was inside
the 95% isodose [17].
Statistical methods
The follow-up period was measured from the first day of
treatment. The Statistical Package for Social Sciences
(SPSS version 16.0) software was used for statistical ana-
lysis. Kaplan-Meier method was used to calculate the cu-
mulative local failure-free survival (LFFS), regional
failure- free survival (RFFS) and overall survival (OS).
Results
Rates of local-regional recurrence
A total of 370 patients were analyzed. Characteristics of
patients, tumor stage and treatment factors were detailed
in Table 1. The median follow-up was 26 months, with a
range from 3 months to 62 months. The 1- and 2-year ac-
tuarial local-regional control rates for all patients were99.7% (95% confidence interval [CI]: 100-99.1%) and
95.5% (95% CI: 93-98%) respectively. The 2-year LFFS,
RFFS and OS were 97.7%, 97.0% and 94.1%, respectively.
At their last follow-up visit, 18 patients (4.9%) devel-
oped clinical or radiographic local-regional recurrences.
78% (14/18) of the patients were locally advanced
(staged T3 or T4). The median time from treatment to
local-regional recurrence was 20.5 months (range 11 to
41 months). Twelve patients with a local-regional recur-
rence were successfully salvaged with surgery alone (4),
chemotherapy alone (4), RT alone (1), neck dissection
and RT (1), or RT and chemotherapy (2). The ultimate
crude local regional control rate was 66.7%. For the six
patients with local-regional recurrences that could not
be salvaged, four patients suffered distant metastasis be-
fore, simultaneously, or shortly after local-regional re-
currence and the other two refused to accept any
treatment.
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Table 2 shows the DVH statistics for patients of local-
regional recurrence. On average, the target volumes had
excellent coverage and only 1.7% of the GTV_P and
0.3% of the GTV_N received <95% of the prescribed
dose. The majority (91%-96%) of the GTV_P and
GTV_N actually received more than 100% of the pre-
scribed dose. A similar situation was found in CTV1
and CTV2. The mean dose to the CTV1 was 65.9Gy
and 56.7Gy to the CTV2. Volume (%) receiving less than
95% of the prescribed dose was 0.7% to CTV1 and 0.4%
to CTV2.
Patterns of failure
In the 18 patients who developed into local-regional re-
currences, 7 patients had isolated regional recurrences,
other 7 patients had isolated local recurrences, and 4 pa-
tients had both local and regional recurrences. 5 patients
had simultaneous distant metastasis, including lung and
bone metastasis.
A total of 25 recurrences were observed in the above 18
patients, 16 (64%) occurred within the 95% isodose lines
and were considered in-field failures; 3(12%) were mar-
ginal, occurring in a steep dose gradient region at the mar-
gin of the high-dose PTV-C, the other 3 (12%) were
outside-field failures. There were 3 missing values because
of the unavailability of the diagnostic image. The sites of
local-regional recurrences are detailed in Table 3.
As show in Table 3, the average minimum, mean and
maximum dose delivered to Vrecur for marginal recurrence
were 28Gy, 61.8Gy and 72.6Gy, respectively. Regarding
the in-field recurrences, the average minimum dose to
Vrecur was 59.3Gy (range 37.6Gy to 69.1Gy). The average
mean dose of radiation to the in-field recurrences was
69.3Gy (range 65.1Gy to 73.5Gy). The average maximum
dose of radiation to the in-field recurrences was 73.5Gy
(range 69.3Gy to 77.3Gy). Figure 1 demonstrates axial
dose distributions through the epicenter of the recurrent
volumes occurring in-field, marginal and outside-field.Table 2 Dose–volume histograms (DVHs) statistics for patient
GTV_P GTV_N
Average (range) Average (ran
Volume (cc) 88.5 (35–140.3) 85 (34.2–167)
Dmax (Gy) 75.5 (71.7–77.6) 73.2 (71.2–75.3
Dmean (Gy) 71.5 (68–72.9) 68.7 (68–69.9)
Dmin (Gy) 59.9 (52.7–65.4) 58.8 (48.4–64.2
V95% 1.7 (0–6.3) 0.3 (0–1.5)
V100% 91.3 (77.3–98.9) 95.6 (90.9–98.9
V110% 0.06 (0–1.1) 0.7 (0–3.8)
GTV_P gross tumor volume of primary tumor, GTV_N gross tumor volume of involv
tumor volume of lymph nodal regions at low risk. Dmax = Maximum dose, Dmean = M
prescribed dose, V100%=% volume receiving >100% of the prescribed dose, V110%=Discussion
There is little controversy that IMRT is the treatment of
choice for NPC because dosimetric studies showed clear
advantages by improving dose conformity for complex
tumor targets and better protection of the adjacent or-
gans [1]. The 1- and 2-year local-regional control rates
of 99.7% and 95.5% in the present study are excellent
and similar to reports from other centers [1-15].
As shown in Table 3, most of the relapses in our study
occurred in locally advanced disease, within or margin-
ally to the high dose region. Three out-field failures were
observed in this study. Patient 7 (staged T3N3b) had
treatment failure within a spared parotid gland. Parotid
node involvement occurs in only 1% of cases [22]. This
low proportion of patients does not justify the inclusion
of this level in local-regional CTV. However, Cannon
et al. [19] suggested that for patients who had multilevel
nodal disease, including disease in level II, and under-
went a neck dissection that could have contributed to
modification of lymphatic drainage, parotid nodes could
be considered for inclusion in local-regional CTV. Pa-
tient 14 (staged T2N1) suffered 3 times of regional re-
currences one after another, two of them occurred in
submandibular nodes. Neck levels IB (submandibular
nodes) were selectively irradiated only if there was ex-
tensive nodal disease on the ipsilateral IIA/IIB region,
extracapsular extension of the IIA lymph nodes, or ton-
silla and lingual root involved by the primary tumor in
our institution. The recent meta-analysis by Ho et al. re-
ported that IB node involvement occured in only 3% of
cases [22]. This low risk of involvement also supports
the elective treatment of level IB. The 3rd relapse occurred
in neck levels IIA which grew alongside the space between
the muscles, and then it was defined as “outside-field” fail-
ures. The potential reason is the neck dissections the pa-
tient subjected to after the previous relapses, which could
have modified his lymphatic drainage.
It is generally recommended that a total dose of 70Gy
with conventional fractionation should be given, but it iss of local-regional recurrence
CTV1 CTV2
ge) Average (range) Average (range)
298.6 (117.8–530.8) 124 (27.1–228.1)
) 75.2 (70.4–77.6) 61.7 (58.9–63.9)
65.9 (62.1–69.2) 56.7 (55.5–57.5)
) 43.4 (17.5–54.5) 43.3 (7-51)
0.7 (0.2–2.1) 0.4 (0–1.4)
) 96.5(92.1–99.1) 96.6 (93.9–99.5)
44 (2.1–76) 5.7 (0–14.5)
ed lymph nodes, CTV1 clinical tumor volume of the high-risk region, CTV2 clinical
ean dose, Dmin = Minimum dose. V95%=%volume receiving < 95% of the
% volume receiving >110% of the prescribed dose.
Table 3 Details of recurrent patients and their local-regional failures
Dose–volume histograms statistics to recurrence volume
















1 T4N3b Local CTV 13.9 69.9 48.5 75.2 97.9 In-field
Regional CTV 2.7 68.9 64.6 71.3 100 In-field
2 T4N1 Local Marginal to CTV 10.5 70 51.5 77 94.3 marginal
3 T4N0 Local CTV 32.9 70.9 37.6 75.4 97.7 In-field
4 T3N3b Local Marginal to CTV 13.9 62.1 11.8 74.1 74.7 marginal
Regional CTV 3.6 67.5 63.9 71.9 100 In-field
5 T2N1 Local CTV 15.1 67.6 60 71.2 100 In-field
6 T1N0 Local CTV 10.2 65.1 53.3 71.7 100 In-field
7 T3N3b Local CTV 2.2 70 63 76.8 100 In-field
Regional Outside CTV 8.4 14.2 11.2 37.7 - outside
8 T3N1 Local GTV 10.6 73.5 69.1 76.3 100 In-field
Regional CTV 5.5 69.6 65.9 73.6 100 In-field
9 T4N0 Local GTV 9.3 72 61.8 74 99.2 In-field
10 T3N2 Local CTV 15.2 71.9 63.3 77.3 100 In-field
11 T4N1 Local CTV 8 72.1 66 73.8 100 In-field
12 T4N3b Regional - - - - - - -
13 T3N2 Regional CTV 20.6 67.8 51.2 72.6 99.6 In-field
14 T2N1 Regional 1 Outside CTV 3.6 45.3 34.6 56.7 - outside
Regional 2 Marginal to CTV 12.6 53.4 20.6 66.7 32.5 marginal
Regional 3 Outside CTV 2.7 54.2 46.6 61.4 19.1 outside
15 T3N2 Regional - - - - - - -
16 T3N3b Regional CTV 4.2 66.5 61.3 69.3 100 In-field
17 T1N2 Regional GTV 2.2 70.1 67.9 72.4 100 In-field
18 T3N3b Regional 1 - - - - - - -
Regional 2 CTV 22.2 65.6 51.4 73 98.8 In-field
CTV clinical target volume, GTV gross tumor volume; V95%=% of volume of failure receiving at least 95% of prescribed total dose, Vrecur the recurrent
tumor volume.
aIn-field refers to 95% of the recurrence volume receiving more than 95% of the prescribed dose. Marginal refers to 20–95% of the recurrence volume receiving
95% of the prescribed dose. Outside refers to less than 20% of the the recurrence volume receiving 95% of the prescribed dose.
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advanced T4 disease, even by IMRT [18]. Ng et al. [1] sug-
gested a possible strategy to lessen the dose constraint cri-
teria of selected neurologic structures (i.e. to sacrifice one
side of the optic nerve or temporal lobe). In our study, pa-
tient 2 (stage T4N1) and patient 4 (stage T3N3b) developed
cavernous sinus and orbital apex recurrence, which were
relatively high locations in NPC. The possible reasons in-
clude missing of subclinical target volume and compromise
with OAR. This also suggests the importance of cooper-
ation between clinicians and radiologists. And great atten-
tion should be paid to the treatment precision for patients
with adequate but very tight dose coverage to the target
volumes, especially for patients with the very steep dose
gradient proximal to the critical neurologic structures.
As show in our study, the main patterns of local-
regional recurrence are in-field failures. A recent Medlinereview by Hong B et al. [23] showed that radioresistance
may be the ultimate cause of a local-regional failure. They
reviewed articles published on clinical and preclinical
studies targeting tumor hypoxia and found that tumor
hypoxia was common in NPC; it was associated with dis-
ease progression and resistance to therapy. In our series,
64% recurrences were located well within the 95% dose re-
gion. In these cases, it is reasonable to assume that there
are nonuniform clonogenic cell density and radiosensitiv-
ity within the same target. Hence, we hope that with the
development of radiation biology, a smarter, nonuniformly
increased dose distribution can be established to reduce
in-field failure as much as possible.
Despite of the prevailing use of IMRT in the treatment
of NPC, optimal target volumes especially the clinical tar-
get volumes (CTVs) have not been sufficiently addressed.
Our results suggest that the definition of CTVs currently
Figure 1 Disease extent for patients having local-regional failures. A, In-field failure. B, Marginal failure. C, Outside-field failure. Left, Pretreatment
magnetic resonance imaging (MRI/CT). Middle, The recurrent tumor volumes were transferred from the diagnostic MRI/CT at the time of recurrence to the
planning computed tomography to show doses delivered to the recurrence sites. Right, MRI/CT at time of failure. IMRT = intensity-modulated radiotherapy.
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control in both the primary disease and involved neck
areas. As reducing high-dose radiation to normal critical
tissues is one of the major purposes of IMRT, it is ques-
tionable that if we can purposefully reduce the coverage of
critical adjacent tissues in CTV for potential subclinical
diseases. Lin et al. [24] found that IMRT using a reduced-
volume technique did not increase incidence of local and
/or regional recurrence that could be attributed to the re-
duction of clinical target volume adjacent to the primary
disease. But further optimization and prospective re-
searches are needed.There were several limitations of this study. First, since
the interval for enrollment was about 5 years, various
factors such as radiation techniques, radiation doses and
chemotherapy regimens have evolved. Second, due to
the relatively small sample size and short time follow-up,
the current findings could only be taken as preliminary.
In order to illustrate patterns of local-regional failure
and possible reasons following primary IMRT for NPC,
longer follow-up and a large sample of uniform treat-
ment are needed for further research.
In conclusion, our data shows excellent local-regional
control by IMRT for NPC. The 1- and 2-year actuarial
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http://www.ro-journal.com/content/9/1/60local-regional control rates for all patients were 99.7% and
95.5% respectively. In-field failures (64%) are the main pat-
terns for local-regional recurrence. The occurrence of
marginal failures implies that great attention should be
paid in all IMRT steps to reduce potential causes of mar-
ginal failures. And studies focusing on radioresistant
should be pursued to reduce in-field failures in the future.
Reducing the coverage of critical adjacent tissues in CTV
purposefully for potential subclinical diseases was worth
of study.
Abbreviations
IMRT: Intensity-modulated radiotherapy; NPC: Nasopharyngeal carcinoma;
RLN: Retropharyngeal lymph node; DVH: Dose-volume histogram.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CD, SH and HY participated in the treatment panning, contributed to the
data collection. HY, CH and FK participated in its design and coordination.
JZ and XC conceived of the study and participated in the data collection.
FK and HY performed the statistical analysis, and drafted the manuscript.
All authors read and approved the final manuscript.
Received: 2 August 2013 Accepted: 16 February 2014
Published: 19 February 2014
References
1. Ng WT, Lee MC, Hung WM, Choi CW, Lee KC, Chan OS, Lee AW: Clinical
outcomes and patterns of failure after intensity-modulated radiotherapy
for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2011,
79(2):420–428.
2. Cao CN, Luo JW, Gao L, Yi JL, Huang XD, Wang K, Zhang SP, Qu Y, Li SY, Cai
WM, Xiao JP, Zhang Z, Xu GZ: Clinical outcomes and patterns of failure
after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma.
Oral Oncol 2013, 49(2):175–181.
3. Wang R, Wu F, Lu H, Wei B, Feng G, Li G, Liu M, Yan H, Zhu J, Zhang Y, Hu
K: Definitive intensity-modulated radiation therapy for nasopharyngeal
carcinoma: long-term outcome of a multicenter prospective study.
J Cancer Res Clin Oncol 2013, 139(1):139–145.
4. Su SF, Han F, Zhao C, Chen CY, Xiao WW, Li JX, Lu TX: Long-term
outcomes of early-stage nasopharyngeal carcinoma patients treated
with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys
2012, 82(1):327–333.
5. Ma BB, Kam MK, Leung SF, Hui EP, King AD, Chan SL, Mo F, Loong H, Yu BK,
Ahuja A, Chan AT: A phase II study of concurrent cetuximab-cisplatin and
intensity-modulated radiotherapy in locoregionally advanced nasopha-
ryngeal carcinoma. Ann Oncol 2012, 23(5):1287–1292.
6. Zhao LN, Zhou B, Shi M, Wang JH, Xiao F, Xu M, Luo SQ, Xue Y, Li JP, Tan
LN: Clinical outcome for nasopharyngeal carcinoma with predominantly
WHO II histology treated with intensity-modulated radiation therapy in
non-endemic region of China. Oral Oncol 2012, 48(9):864–869.
7. Xiao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, Deng XW, Lu TX, Cui NJ,
Zhao C: Local control, survival, and late toxicities of locally advanced
nasopharyngeal carcinoma treated by simultaneous modulated accelerated
radiotherapy combined with cisplatin concurrent chemotherapy: long-term
results of a phase 2 study. Cancer 2011, 117(9):1874–1883.
8. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ, Ma J:
How does intensity-modulated radiotherapy versus conventional two-
dimensional radiotherapy influence the treatment results in nasopharyngeal
carcinoma patients? Int J Radiat Oncol Biol Phys 2011, 80(3):661–668.
9. Wong FC, Ng AW, Lee VH, Lui CM, Yuen KK, Sze WK, Leung TW, Tung SY:
Whole-field simultaneous integrated-boost intensity-modulated radio-
therapy for patients with nasopharyngeal carcinoma. Int J Radiat Oncol
Biol Phys 2010, 76(1):138–145.
10. Tham IW, Hee SW, Yeo RM, Salleh PB, Lee J, Tan TW, Fong KW, Chua ET,
Wee JT: Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre singapore experience.
Int J Radiat Oncol Biol Phys 2009, 75(5):1481–1486.
11. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ: Intensity-
modulated radiation therapy (IMRT) for nasopharynx cancer: update of
the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys
2006, 64(1):57–62.
12. Kwong DL, Sham JS, Leung LH, Cheng AC, Ng WM, Kwong PW, Lui WM,
Yau CC, Wu PM, Wei W, Au G: Preliminary results of radiation dose
escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat
Oncol Biol Phys 2006, 64(2):374–381.
13. Kam MK, Teo PM, Chau RM, Cheung KY, Choi PH, Kwan WH, Leung SF, Zee
B, Chan AT: Treatment of nasopharyngeal carcinoma with intensity-
modulated radiotherapy: the Hong Kong experience. Int J Radiat
Oncol Biol Phys 2004, 60(5):1440–1450.
14. Liu MT, Hsieh CY, Chang TH, Lin JP, Huang CC, Wang AY: Prognostic
factors affecting the outcome of nasopharyngeal carcinoma.
Jpn J Clin Oncol 2003, 33(10):501–508.
15. Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P,
Weinberg V, Fu KK: Intensity-modulated radiotherapy in the treatment
of nasopharyngeal carcinoma: an update of the UCSF experience.
Int J Radiat Oncol Biol Phys 2002, 53(1):12–22.
16. Kwong DL, Pow EH, Sham JS, McMillan AS, Leung LH, Leung WK, Chua DT,
Cheng AC, Wu PM, Au GK: Intensity-modulated radiotherapy for early-stage
nasopharyngeal carcinoma: a prospective study on disease control and
preservation of salivary function. Cancer 2004, 101(7):1584–1593.
17. Dawson LA, Anzai Y, Marsh L, Martel MK, Paulino A, Ship JA, Eisbruch A:
Patterns of local-regional recurrence following parotid-sparing conformal
and segmental intensity-modulated radiotherapy for head and neck
cancer. Int J Radiat Oncol Biol Phys 2000, 46(5):1117–1126.
18. Orlandi E, Tomatis S, Potepan P, Bossi P, Mongioj V, Carrara M, Palazzi M,
Franceschini M, Bergamini C, Locati L, Iannacone E, Guzzo M, Ibba T, Crippa
F, Licitra L, Pignoli E, Fallai C: Critical analysis of locoregional failures
following intensity-modulated radiotherapy for nasopharyngeal
carcinoma. Future Oncol 2013, 9(1):103–114.
19. Cannon DM, Lee NY: Recurrence in region of spared parotid gland after
definitive intensity-modulated radiotherapy for head and neck cancer.
Int J Radiat Oncol Biol Phys 2008, 70(3):660–665.
20. ICRU Report 50: Prescribing, Recording, and Reporting Photon Beam Therapy.
Bethesda, MD: International Commission on Radiation Units and
Measurements; 1993.
21. ICRU Report 62: Prescribing, Recording, and Reporting Photon Beam Therapy
(Supplement to ICRU Report 50). Bethesda, MD: International Commission on
Radiation Units and Measurements; 1999.
22. Ho FC, Tham IW, Earnest A, Lee KM, Lu JJ: Patterns of regional lymph
node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical
evidence. BMC Cancer 2012, 12:98.
23. Hong B, Lui VW, Hashiguchi M, Hui EP, Chan AT: Targeting tumor hypoxia
in nasopharyngeal carcinoma. Head Neck 2013, 35(1):133–145.
24. Lin S, Pan J, Han L, Zhang X, Liao X, Lu JJ: Nasopharyngeal carcinoma
treated with reduced-volume intensity-modulated radiation therapy:
report on the 3-year outcome of a prospective series. Int J Radiat Oncol
Biol Phys 2009, 75(4):1071–1078.
doi:10.1186/1748-717X-9-60
Cite this article as: Kong et al.: Patterns of local-regional failure after
primary intensity modulated radiotherapy for nasopharyngeal carcinoma.
Radiation Oncology 2014 9:60.
